IRIS
BRUERA, GEMMA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.622
EU - Europa 944
AS - Asia 777
SA - Sud America 139
Continente sconosciuto - Info sul continente non disponibili 87
AF - Africa 16
Totale 3.585
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.579
SG - Singapore 363
RU - Federazione Russa 199
IE - Irlanda 189
IT - Italia 161
CN - Cina 150
BR - Brasile 112
DE - Germania 102
VN - Vietnam 84
SE - Svezia 65
TR - Turchia 63
HK - Hong Kong 52
FI - Finlandia 47
GB - Regno Unito 41
FR - Francia 40
UA - Ucraina 39
CZ - Repubblica Ceca 21
CA - Canada 19
IN - India 18
AR - Argentina 9
ES - Italia 9
BD - Bangladesh 8
MX - Messico 8
PL - Polonia 8
IQ - Iraq 7
ID - Indonesia 6
CL - Cile 5
PH - Filippine 5
DM - Dominica 4
JP - Giappone 4
AT - Austria 3
BE - Belgio 3
EC - Ecuador 3
LT - Lituania 3
PK - Pakistan 3
PT - Portogallo 3
RO - Romania 3
TN - Tunisia 3
VE - Venezuela 3
ZA - Sudafrica 3
BN - Brunei Darussalam 2
CR - Costa Rica 2
JM - Giamaica 2
MA - Marocco 2
NL - Olanda 2
PR - Porto Rico 2
PY - Paraguay 2
SA - Arabia Saudita 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AG - Antigua e Barbuda 1
AO - Angola 1
BO - Bolivia 1
BY - Bielorussia 1
CO - Colombia 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
GF - Guiana Francese 1
GH - Ghana 1
GM - Gambi 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
IL - Israele 1
JO - Giordania 1
KE - Kenya 1
LV - Lettonia 1
MD - Moldavia 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PS - Palestinian Territory 1
RS - Serbia 1
SC - Seychelles 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TL - Timor Orientale 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 3.498
Salva come PNG Salva come JPEG
Città #
Chandler 216
Singapore 196
Dublin 189
Jacksonville 159
Ashburn 152
San Jose 146
Dallas 107
Council Bluffs 83
Santa Clara 64
Boardman 53
Hong Kong 51
New York 40
Beijing 33
The Dalles 32
Ho Chi Minh City 28
Izmir 26
Munich 26
Nanjing 26
Bremen 25
Lawrence 25
Princeton 25
Milan 22
Wilmington 22
Brno 21
Moscow 21
Helsinki 20
Hanoi 17
Columbus 16
Rome 16
São Paulo 16
Los Angeles 15
Pescara 12
Nanchang 11
San Mateo 11
Dong Ket 10
Lauterbourg 10
Denver 9
Turku 9
Ann Arbor 8
L’Aquila 8
Falkenstein 7
Hebei 7
North Bergen 7
Woodbridge 7
Lappeenranta 6
Orem 6
Warsaw 6
Brooklyn 5
Chennai 5
Frankfurt am Main 5
Kunming 5
London 5
Montreal 5
Naples 5
Tianjin 5
Toronto 5
Changsha 4
Des Moines 4
Roseau 4
San Francisco 4
Seattle 4
Tokyo 4
Ankara 3
Atlanta 3
Baghdad 3
Brussels 3
Campinas 3
Dearborn 3
Glenside 3
Haiphong 3
Hefei 3
Jiaxing 3
L'aquila 3
Miano 3
Mountain View 3
New Delhi 3
Omaha 3
Philadelphia 3
Quezon City 3
Redwood City 3
Shenyang 3
Stockholm 3
Waltham 3
Washington 3
Bandar Seri Begawan 2
Bauru 2
Betim 2
Borås 2
Brasília 2
Buenos Aires 2
Caracas 2
Chapecó 2
Charleston 2
Chicago 2
Delhi 2
Duhok 2
Gramado 2
Guangzhou 2
Houston 2
Hải Dương 2
Totale 2.189
Salva come PNG Salva come JPEG
Nome #
The prevalent KRAS exon 2 c.35 G > A mutation in metastatic colorectal cancer patients: a biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? 206
KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease. 198
Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study 182
Dose-finding study of oxaliplatin associated to capecitabine based preoperative chemoradiotherapy in locally advanced rectal cancer 167
Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases 166
Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A 164
KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. 162
Multidisciplinary palliation for unresectable recurrent rectal cancer: Hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study 158
two simulteneous and very uncommom pi3kca mutations in a liver metastasis from colorectal cancer patient with aggressive and resistant disease 150
Dose-dense nonpegylated liposomal doxorubicin and docetaxel combination in breast cancer: Dose-finding study 148
Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). 143
Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease 133
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy 131
Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: An experience of multidisciplinary management in clinical practice 131
Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient WithKRASMutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy 125
Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: Recommended schedule for expected activity and safety and phase II study 122
Effectiveness and safety of intensive triplet chemotherapy plus bevecizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer 118
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. 118
Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice 117
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. 117
Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy. Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevaizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52 113
Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments 113
Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer 112
Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice 108
Stravaso da antracicline: il punto di vista dell’oncologo. Caso clinico. 101
PSA as the driving biomarker to manage low- and intermediate-risk prostate cancer patients in clinical practice 82
Totale 3.585
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.697
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.697
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202291 0 0 0 7 5 0 0 7 10 0 9 53
2022/2023579 27 42 2 79 55 67 2 32 244 0 12 17
2023/2024135 19 9 9 12 8 38 8 4 0 2 3 23
2024/2025632 35 12 43 38 86 46 99 53 131 15 54 20
2025/20261.120 63 107 73 103 132 95 168 34 95 183 50 17
2026/2027347 26 39 69 213 0 0 0 0 0 0 0 0
Totale 3.585